205+
Type 2 diabetes clinical studies completed
140+
Type 1 diabetes clinical studies completed
Leading Provider
More early phase type 1 and type 2 diabetes clinical studies than any other U.S. provider*
*Data from Informa’s Citeline April 2024
Advancing Diabetes Drug and Device Development Through Focused Expertise
As a diabetes CRO, we provide customized services and solutions for every stage of your metabolic disease research program. From study startup, participant recruitment, and site engagement to data analysis and study completion, we ensure comprehensive support. ProSciento has been involved in the development of all medically relevant classes of glucose-lowering drugs, including new insulin analogs, novel insulin formulations, and biosimilar insulins.
Enhancing Diabetes Patient Access and Engagement
We are dedicated to bringing new treatments to individuals impacted by type 1 and type 2 diabetes. ProSciento has pioneered approaches for improved patient access and engagement. By listening to patient perspectives, we understand which tools and strategies work best to support sites and engage with patients from screening through study completion and beyond.
Scientific Community and Advocacy Support
With a commitment to advancing treatments for obesity, diabetes, and steatotic liver diseases, we contribute to future advancements in the field. This dedication is reflected in our extensive publication record, supporting clients in publishing outcomes with more than 330 poster presentations and peer-reviewed articles. By partnering with advocacy organizations, we promote education and further support individuals affected by metabolic diseases.
